SynthesisFrontiers in medicine2026
Expression of Claudin-18.2 in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Claudin-18.2 (CLDN18.2), a tight junction protein, has emerged as a promising molecular target in gastrointestinal cancers. However, its expression pattern and clinicopathological relevance in pancreatic ductal adenocarcinoma (PDAC) remain unclear. Objective: To assess the prevalence, tumor-specific, and clinicopathological associations of CLDN18.2 expression in PDAC, and to identify sources of heterogeneity to clarify its value as a therapeutic target. Methods: A systematic search across six major databases was conducted from inception to August 2025 in accordance with PRISMA guidelines. Included studies evaluated CLDN18.2 expression in adult PDAC using defined immunohistochemistry protocols. Random-effects models estimated pooled prevalence and odds ratios (ORs), with subgroup analyses exploring heterogeneity. Results: Sixteen studies including 2,025 patients with PDAC were included. The pooled prevalence of CLDN18.2 expression was 51.60% (95% CI: 40.93-62.19), with substantial heterogeneity (I Conclusion: CLDN18.2 is frequently expressed in PDAC and shows high tumor specificity, supporting its relevance as a therapeutic biomarker. Despite assay variability, even under stringent clinical trial criteria, a meaningful subset of patients may qualify for CLDN18.2-targeted therapy. These findings highlight the need for standardized testing and further clinical evaluation of CLDN18.2-directed strategies in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.